LRG Staff

Home/LRG Staff

About LRG Staff

This author has not yet filled in any details.
So far LRG Staff has created 479 blog entries.

Blueprint & Deciphera Celebrate GIST Awareness Day 2020 – Galleries

Blueprint Medicines and Deciphera Pharmaceuticals celebrated GIST Awareness Day (GAD), July 13th, 2020, with Virtual Walks across the U.S. This year's GIST Awareness Day theme was #GISTHope.

By |2020-07-20T08:41:11-04:00July 17th, 2020|Advocacy, News, Photos|

RARE Partnership in Advocacy, Funding, and Research for Gastrointestinal Stromal Tumor

Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.

By |2020-07-15T14:11:15-04:00July 14th, 2020|Advocacy, News, Research, SDH-Deficient GIST|

Life Raft Group Collaborates on White Paper Published by Cancer Leaders

The Life Raft Group has been an integral part of a pan-cancer Working Group designed to determine consistent terminology around biomarker or mutational testing. The goal is to communicate to patients and the larger community in plain, patient friendly and consistent language what these terms mean, and how they impact on precision medicine.

By |2020-07-07T10:21:41-04:00July 7th, 2020|Advocacy, News|

LRG Webcast Series: GIST: How to Understand Your Pathology Report

In this webinar, we discussed how to interpret your pathology report. We covered interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.

By |2020-07-20T10:42:19-04:00June 30th, 2020|GIST Education, Mutations, Webcast|

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|
Go to Top